BURLINGAME, Calif., June 4, 2008 (PRIME NEWSWIRE) -- Urigen Pharmaceuticals, Inc. (OTCBB:URGP) announced that William Garner, MD, President and CEO, will present an overview of the Company at the RedChip 2008 Small-Cap Investor Conference tomorrow in San Francisco.
Dr. Garner will review Urigen's pipeline, including recent results of a Phase II trial of its lead compound URG101, at the Palace Hotel on Thursday, June 5th at 10:10 AM PDT. A live audio webcast and archive of the presentation will be available at www.urigen.com.
Earlier this year, Urigen announced positive results at interim analysis of a multi-center, double-blind, placebo-controlled, crossover-designed Phase II clinical trial of URG101 in patients with Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC).
About Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC)
Painful Bladder Syndrome/Interstitial Cystitis is a recognized medical condition with increased frequency of diagnosis. PBS/IC is characterized by bladder pain, urinary urgency and nocturia. Few IC treatments exist, and no approved therapies are available for PBS. Today, there are an estimated 10.5 million women and men in North America who suffer from PBS/IC.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets painful bladder syndrome/interstitial cystitis which affects approximately 10.5 million men and women in North America. Urigen's URG301 project targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.